GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aprinoia Therapeutics Inc (NAS:APRI) » Definitions » EPS without NRI

Aprinoia Therapeutics (Aprinoia Therapeutics) EPS without NRI : $-0.80 (TTM As of Jun. 2023)


View and export this data going back to 2050. Start your Free Trial

What is Aprinoia Therapeutics EPS without NRI?

Aprinoia Therapeutics's earnings per share without non-recurring items for the six months ended in Jun. 2023 was $-0.27. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.80.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Aprinoia Therapeutics's EPS without NRI or its related term are showing as below:

APRI's 3-Year EPS without NRI Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 4.8
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

Aprinoia Therapeutics's EPS (Diluted) for the six months ended in Jun. 2023 was $-0.26. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.78.

Aprinoia Therapeutics's EPS (Basic) for the six months ended in Jun. 2023 was $-0.26. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.78.


Aprinoia Therapeutics EPS without NRI Historical Data

The historical data trend for Aprinoia Therapeutics's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aprinoia Therapeutics EPS without NRI Chart

Aprinoia Therapeutics Annual Data
Trend Dec21 Dec22
EPS without NRI
-0.84 -1.01

Aprinoia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23
EPS without NRI - -0.49 -0.52 -0.27

Competitive Comparison of Aprinoia Therapeutics's EPS without NRI

For the Biotechnology subindustry, Aprinoia Therapeutics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aprinoia Therapeutics's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aprinoia Therapeutics's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Aprinoia Therapeutics's PE Ratio without NRI falls into.



Aprinoia Therapeutics EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aprinoia Therapeutics  (NAS:APRI) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Aprinoia Therapeutics EPS without NRI Related Terms

Thank you for viewing the detailed overview of Aprinoia Therapeutics's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Aprinoia Therapeutics (Aprinoia Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.

Aprinoia Therapeutics (Aprinoia Therapeutics) Headlines

No Headlines